Crown Laboratories hikes offer price for Revance to $3.65/share, extends existing tender offer
Crown Laboratories Tuesday increased its offer price to acquire Revance Therapeutics (NASDAQ:RVNC) to $3.65 per share, a $0.55 per share increase. Improved offer unanimously approved by Revance ...